Treatment of recurrent depression

@article{Fava2006TreatmentOR,
  title={Treatment of recurrent depression},
  author={Giovanni Andrea Fava and Seung K. Park and Nicoletta Sonino},
  journal={Expert Review of Neurotherapeutics},
  year={2006},
  volume={6},
  pages={1735 - 1740}
}
Approximately eight out of ten people experiencing a major depressive episode will have one or more further episodes during their lifetime: a recurrent major depressive disorder. Prolongation or lifelong pharmacotherapy has emerged as the main therapeutic tool for preventing relapse in depression. However, outcome after discontinuation of antidepressants does not seem to be affected by the duration of their administration. Loss of clinical effects, despite adequate compliance, has also emerged… 
Heart Rate Variability Biofeedback Stress Relief Program for Depression*. A Replicated Single-Subject Design
TLDR
The intervention had more clinical impact on resilience-related outcome measures than on symptoms, and the small sample size does not permit generalization of the results.
The Role of Early Life Stress in HPA Axis and Depression
TLDR
This review examines the emerging literature on the relationship between stress, hypothalamic-pituitary-adrenal (HPA) axis function, and depression and the role of early life stress as an important risk factor for HPA axis dysregulation and suggests that this dysregulation of the HPAaxis is partially attributable to an imbalance between glucocorticoid and mineralocortioid receptors.
Towards a neuroimaging biomarker of depression vulnerability
TLDR
It is argued that unlike the amygdala hyperactivity and prefrontal hypoactivity observed during MDD episodes, prefrontal hyperactivity may be a characteristic of dysphoric cognition during symptom remission that indicates MDD vulnerability and relapse risk.
Early life stress, HPA axis, and depression
TLDR
This review examines the emerging literature on the relationship between stress, hypothalamic-pituitary-adrenal (HPA) axis function, and depression and the role of early life stress as an important risk factor for HPA axis dysregulation and suggests this dysregulation is partially attributable to an imbalance between glucocorticoid and mineralocortioid receptors.
A lifespan view of anxiety disorders
TLDR
Data on anxiety disorders as they appear in older adults, as compared with earlier in life is presented and optimal management of anxiety disorders across the lifespan is described, in “eight simple steps” for practitioners.
Effectiveness in mental health: a review and rethink of some basic assumptions and common practices
Despite recent advances in mental health research and treatment, prevalence rates remain high and stable in many countries around the globe. Current efforts to address the problem largely focus on
Autophagy Induction and Accumulation of Phosphorylated Tau in the Hippocampus and Prefrontal Cortex of Adult C57BL/6 Mice Subjected to Adolescent Fluoxetine Treatment.
TLDR
Juvenile FLX treatment may have enduring effects in the neuronal protein degradation machinery, which could adversely influence clearance of abnormal proteins, potentially predisposing individuals to developing AD in later life.
Chronic Depression
  • Kim Lavoie
  • Psychology
    Encyclopedia of Behavioral Medicine
  • 2020
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Treatment of Recurrent Depression
TLDR
Despite an impressive amount of research into the treatment of depression, there is still a paucity of studies addressing the specific problems that prevention of recurrent depression entails and it is important to discuss with the patient the various therapeutic options and to adapt strategies to the specific needs of patients.
Treatment Approaches to Major Depressive Disorder Relapse
TLDR
The results generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant.
Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
TLDR
The patients relapsing after initially responding to fluoxetine can benefit from an increase in fluoxettine dose, and results generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant.
Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
TLDR
The results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted and generally support reinitiation of the same antidepressant as a 'first-line' treatment strategy in patients who relapsed after stopping a previously effective antidepressant.
Treatment Approaches to Major Depressive Disorder Relapse
TLDR
The results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted and generally support reinitiation of the same antidepressant as a ‘first-line’ treatment strategy in patients who relapsed after stopping a previously effective antidepressant.
Six-year outcome of cognitive behavior therapy for prevention of recurrent depression.
TLDR
Cognitive behavior treatment of residual symptoms was found to yield a significantly lower relapse rate than clinical management in recurrent depression at a 2-year follow-up, suggesting that the sequential use of cognitive behavior treatment after pharmacotherapy may improve the long-term outcome in recurrent depressed.
Tolerance in Antidepressant Treatment
TLDR
Observations are provided from their long-term collaborative study of outpatients with moderately severe, recurrent unipolar depression who relapsed during longterm treatment with (B)-fluoxetine, extending previous observations that increasing fluoxettine doses can rescue some late failures.
Discontinuing Antidepressant Treatment in Major Depression
TLDR
Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates, and differences in relapses off versus on antidepressants fell markedly with longer follow‐up, but gradual discontinuation (dose‐tapering or use of long‐acting agents) did not yield lower relapse rate.
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
TLDR
Cognitive therapy has an enduring effect that extends beyond the end of treatment and seems to be as effective as keeping patients on medication.
Can long-term treatment with antidepressant drugs worsen the course of depression?
  • G. Fava
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2003
TLDR
The possibility that antidepressant drugs may worsen the course of depression needs to be tested, even though its scientific exploration is likely to encounter considerable methodological and ideological difficulties.
...
...